User:Mr. Ibrahem/Tetrabenazine

Mr. Ibrahem/Tetrabenazine
Clinical data
Trade names	Xenazine, Xentra, Nitoman, others
Other names	Ro-1-9569
AHFS/Drugs.com	Consumer Drug Information
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth (tablets)
Drug class	Vesicular monoamine transporter 2 inhibitor
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	Low, extensive first pass effect
Protein binding	82–85%
Metabolism	Liver (CYP2D6-mediated)
Elimination half-life	10 hours parent compound (2 to 8 hours active metabolites)
Excretion	Kidney (~75%) and fecal (7–16%)
Identifiers
	IUPAC name (SS,RR)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-pyrido[2,1-a]isoquinolin-2-one;
Chemical and physical data
Formula	C19H27NO3
Molar mass	317.429 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES O=C3C(CC(C)C)CN2C(c1c(cc(OC)c(OC)c1)CC2)C3;
	InChI InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3 ; Key:MKJIEFSOBYUXJB-UHFFFAOYSA-N ;
	(verify)

Tetrabenazine, sold under the brand name Xenazine among other, is a medication used to treat certain movement disorders, including Huntington chorea and tardive dyskinesia.^[1]^[4] It is taken by mouth.^[4]

Common side effects include sleepiness, depression, irritability, poor balance, nausea, and falls.^[1] Other side effects may include high prolactin, low blood pressure, QT prolongation, neuroleptic malignant syndrome, and trouble swallowing.^[1] It is a vesicular monoamine transporter 2 inhibitor.^[1]

Tetrabenazine was approved for medical use in the United States in 2008.^[1] It is available as a generic medication.^[4] In the United Kingdom 112 tablets of 25 mg costs the NHS about 100 pounds as of 2021.^[4] This amount in the United States costs about 1,500 USD.^[5]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h "Tetrabenazine". drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2021. Retrieved 1 October 2021.
^ Yero, T.; Rey, J. A. (2008). "Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington's Disease". P & T: A Peer-Reviewed Journal for Formulary Management. 33 (12): 690–694. PMC 2730806. PMID 19750050.
^ "Xenazine (tetrabenazine) Tablets, for Oral Use. Full Prescribing Information. Revised: 6/2015" (PDF). H. Lundbeck A/S. Archived (PDF) from the original on 31 July 2018. Retrieved 9 December 2015.
^ ^a ^b ^c ^d ^e BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 425. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
^ "Tetrabenazine Generic Xenazine". Retrieved 1 October 2021.

[AHFS2021-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h "Tetrabenazine". drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2021. Retrieved 1 October 2021.

[hl-2] Yero, T.; Rey, J. A. (2008). "Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington's Disease". P & T: A Peer-Reviewed Journal for Formulary Management. 33 (12): 690–694. PMC 2730806. PMID 19750050.

[PI-3] "Xenazine (tetrabenazine) Tablets, for Oral Use. Full Prescribing Information. Revised: 6/2015" (PDF). H. Lundbeck A/S. Archived (PDF) from the original on 31 July 2018. Retrieved 9 December 2015.

[BNF80-4] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 425. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[5] "Tetrabenazine Generic Xenazine". Retrieved 1 October 2021.

[1]

[2]

[3]

[4]

[5]